Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study.

The intracellular activity of the p53 tumor suppressor protein is regulated through a feedback loop involving its transcriptional target, mdm2. We present a simple mathematical model suggesting that, under certain circumstances, oscillations in p53 and Mdm2 protein levels can emerge in response to a stress signal. A delay in p53-dependent induction of Mdm2 is predicted to be required, albeit not sufficient, for this oscillatory behavior. In line with the predictions of the model, oscillations of both p53 and Mdm2 indeed occur on exposure of various cell types to ionizing radiation. Such oscillations may allow cells to repair their DNA without risking the irreversible consequences of continuous excessive p53 activation.

[1]  B. Kennedy,et al.  NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. , 2000, Genes & development.

[2]  D. Notterman,et al.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. , 2000, Genes & development.

[3]  T. Halazonetis,et al.  Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. , 2000, Genes & development.

[4]  Y Taya,et al.  The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. , 2000, Genes & development.

[5]  M. Saraste,et al.  FEBS Lett , 2000 .

[6]  Y. Shiloh,et al.  Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Oren.  Regulation of the p53 Tumor Suppressor Protein* , 1999, The Journal of Biological Chemistry.

[8]  D. Lane,et al.  Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function. , 1999, Experimental cell research.

[9]  G. Wahl,et al.  p53 regulation by post-translational modification and nuclear retention in response to diverse stresses , 1999, Oncogene.

[10]  D. Meek,et al.  Mechanisms of switching on p53: a role for covalent modification? , 1999, Oncogene.

[11]  B. Aguda,et al.  A quantitative analysis of the kinetics of the G(2) DNA damage checkpoint system. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  E. Rogakou,et al.  Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in Vivo , 1999, The Journal of cell biology.

[13]  A. Levine,et al.  P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[14]  B. Geiger,et al.  Excess β‐catenin promotes accumulation of transcriptionally active p53 , 1999, The EMBO journal.

[15]  V. Rotter,et al.  Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery , 1999, FEBS letters.

[16]  Charles J. Sherr,et al.  Nucleolar Arf sequesters Mdm2 and activates p53 , 1999, Nature Cell Biology.

[17]  Y Taya,et al.  DNA damage‐inducible phosphorylation of p53 at N‐terminal sites including a novel site, Ser20, requires tetramerization , 1999, The EMBO journal.

[18]  T. Unger,et al.  Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2 , 1999, The EMBO journal.

[19]  A. Takahashi,et al.  Low-dose-rate radiation attenuates the response of the tumor suppressor TP53. , 1999, Radiation research.

[20]  M. Oren,et al.  Mdm2: The Ups and Downs , 1999, Molecular medicine.

[21]  R. Honda,et al.  Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 , 1999, The EMBO journal.

[22]  W P Bennett,et al.  Molecular epidemiology of human cancer risk: gene–environment interactions and p53 mutation spectrum in human lung cancer , 1999, The Journal of pathology.

[23]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[24]  A. Levine,et al.  Functions of the MDM2 oncoprotein , 1999, Cellular and Molecular Life Sciences CMLS.

[25]  F. Kashanchi,et al.  Phosphorylation of p53 Serine 15 Increases Interaction with CBP* , 1998, The Journal of Biological Chemistry.

[26]  B. Kuehl,et al.  Differential expression of p53, p21waf1/cip1 and hdm2 dependent on DNA damage in Bloom's syndrome fibroblasts. , 1998, Carcinogenesis.

[27]  V. Adler,et al.  Mdm2 association with p53 targets its ubiquitination , 1998, Oncogene.

[28]  A. Giaccia,et al.  The complexity of p53 modulation: emerging patterns from divergent signals. , 1998, Genes & development.

[29]  C. Sherr,et al.  Tumor surveillance via the ARF-p53 pathway. , 1998, Genes & development.

[30]  V. Adler,et al.  JNK targets p53 ubiquitination and degradation in nonstressed cells. , 1998, Genes & development.

[31]  E. Stavridi,et al.  ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins , 1998, Nature Genetics.

[32]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[33]  A. Levine,et al.  Nucleo‐cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein , 1998, The EMBO journal.

[34]  M L Agarwal,et al.  The p53 Network* , 1998, The Journal of Biological Chemistry.

[35]  S. Ōmura,et al.  mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[36]  A. Balmain,et al.  Stochastic modelling of tumorigenesis in p53 deficient mice. , 1998, British Journal of Cancer.

[37]  David P. Lane,et al.  Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo , 1997, Current Biology.

[38]  Yoichi Taya,et al.  DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.

[39]  Wei Gu,et al.  Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain , 1997, Cell.

[40]  R. Tjian,et al.  Repression of p53-mediated transcription by MDM2: a dual mechanism. , 1997, Genes & development.

[41]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[42]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[43]  G. Wahl,et al.  p53 Mediates Permanent Arrest over Multiple Cell Cycles in Response to γ-Irradiation , 1997 .

[44]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[45]  M. Kubbutat,et al.  Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability , 1997, Molecular and cellular biology.

[46]  X. Chen,et al.  p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. , 1996, Genes & development.

[47]  Chi-Ying F. Huang,et al.  Ultrasensitivity in the mitogen-activated protein kinase cascade. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Minden,et al.  Translational regulation of human p53 gene expression. , 1996, The EMBO journal.

[49]  A. Levine,et al.  mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein , 1996, Molecular and cellular biology.

[50]  M. Oren,et al.  Cell type‐specific inhibition of p53‐mediated apoptosis by mdm2. , 1996, The EMBO journal.

[51]  L. Israel.  Tumour progression: random mutations or an integrated survival response to cellular stress conserved from unicellular organisms? , 1996, Journal of theoretical biology.

[52]  V. Rotter,et al.  Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[53]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[54]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[55]  W. Deppert,et al.  Cell-specific transcriptional activation of the mdm2-gene by ectopically expressed wild-type form of a temperature-sensitive mutant p53. , 1995, Oncogene.

[56]  D. Lane,et al.  Two Distinct Signaling Pathways Activate the Latent DNA Binding Function of p53 in a Casein Kinase II-independent Manner (*) , 1995, Journal of Biological Chemistry.

[57]  V. Rotter,et al.  Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[58]  A. Levine,et al.  The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[59]  A. Levine,et al.  Human TAFII31 protein is a transcriptional coactivator of the p53 protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[60]  P. O'Connor,et al.  Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. , 1995, Oncogene.

[61]  R. Tjian,et al.  p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. , 1995, Science.

[62]  G. Wahl,et al.  DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. , 1994, Genes & development.

[63]  M. Oren,et al.  Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. , 1994, Genes & development.

[64]  A. Levine,et al.  The mdm-2 gene is induced in response to UV light in a p53-dependent manner. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[65]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[66]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[67]  M. Gerretsen,et al.  A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. , 1990, British Journal of Cancer.

[68]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[69]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[70]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[71]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[72]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.

[73]  D. Koshland,et al.  An amplified sensitivity arising from covalent modification in biological systems. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[74]  W. Gardner,et al.  Carcinogenesis , 1961, The Yale Journal of Biology and Medicine.